However, the percentages of CD19 + B-cells in CIDP patients with IVIg treatment were significantly increased compared to untreated and healthy controls, as well as patients under steroid treatment, in contrast to the previous two studies including dysimmune neuropathy patients treated with IVIg [24, 25]. The gene discussed is CD19; the disease is chronic inflammatory demyelinating polyradiculoneuropathy.